Drug Profile
Research programme: phosphodiesterase V inhibitors - VIVUS
Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator VIVUS
- Class
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction; Premature ejaculation
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
- 18 Sep 2006 Discontinued - Preclinical for Premature ejaculation in USA (unspecified route)
- 04 Jul 2002 Preclinical trials in Premature ejaculation in USA (unspecified route)